Publications by authors named "Thomas Fey"

Claim this Profile
P
Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
Timothy A Esbenshade, Kaitlin E Browman, Thomas R Miller, Kathleen M Krueger, Victoria Komater-Roderwald, Thomas A Fey

J Pharmacol Exp Ther· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.
Arturo Perez-Medrano, Michael E Brune, Steven A Buckner, Michael J Coghlan, Thomas A Fey

J Med Chem· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression.
Yung-Wu Chen, Morey L Smith, Michael Sheets, Steve Ballaron, James M Trevillyan, Thomas A Fey

J Cardiovasc Pharmacol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Jeffrey J Rohde, Marina A Pliushchev, Bryan K Sorensen, Dariusz Wodka, Qi Shuai, Thomas A Fey

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.
Zhili Xin, Michael D Serby, Hongyu Zhao, Christi Kosogof, Bruce G Szczepankiewicz, Thomas A Fey

J Med Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists.
Michael D Serby, Hongyu Zhao, Bruce G Szczepankiewicz, Christi Kosogof, Zhili Xin, Thomas A Fey

J Med Chem· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice.
Eugene N Bush, Robin Shapiro, Michael E Brune, Victoria E Knourek-Segel, Brian A Droz, Thomas Fey

Endocrine· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular disease in chronic kidney failure: the role of VDR activators.
J Ruth Wu-Wong, Jin Tian, Masaki Nakane, Junli Ma, Thomas A Fey

Curr Opin Investig Drugs· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs.
Ivan Milicic, Steven A Buckner, Anthony Daza, Michael Coghlan, Thomas A Fey

Eur J Pharmacol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of Vitamin D analogs on bone formation and resorption.
Masaki Nakane, Thomas A Fey, Doug B Dixon, Junli Ma, Michael E Brune

J Steroid Biochem Mol Biol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapamycin analogs with reduced systemic exposure.
Rolf Wagner, Karl W Mollison, Luping Liu, Cynthia L Henry, Teresa A Rosenberg, Thomas Fey

Bioorg Med Chem Lett· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.
Philip R Kym, Rajesh Iyengar, Andrew J Souers, John K Lynch, Andrew S Judd, Thomas Fey

J Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.
Peer B Jacobson, Thomas W von Geldern, Lars Ohman, Marie Osterland, Jiahong Wang, Thomas Fey

J Pharmacol Exp Ther· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892.
Murali Gopalakrishnan, Steven A Buckner, Char-Chang Shieh, Thomas Fey, Adebola Fabiyi

Br J Pharmacol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent K(ATP) opener that selectively inhibits spontaneous bladder contractions.
William A Carroll, Robert J Altenbach, Hao Bai, Jorge D Brioni, Michael E Brune, Thomas A Fey

J Med Chem· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ATP-sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction.
Thomas A Fey, Murali Gopalakrishnan, James G Strake, Linda L King, Jorge D Brioni

Neurourol Urodyn· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. in vivo characterization.
Michael E Brune, Thomas A Fey, Jorge D Brioni, James P Sullivan, Michael Williams

J Pharmacol Exp Ther· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis